Myeloid-derived suppressor cells expand during breast cancer progression and promote tumor-induced bone destruction

OncoImmunology

Volumn 1, Issue 9, 2012, Pages 1484-1494

  Danilin, Sabrina ^a,b   Merkel, Alyssa R ^a,c   Johnson, Joshua R ^a   Johnson, Rachelle W ^a,c,d   Edwards, James R ^a   Sterling, Julie A ^a,c,d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone metastasis; Breast cancer; Myeloid derived suppressor cells (MDSCs); Osteoclasts PTHrP; TGF

Indexed keywords

CD11B ANTIGEN; COLONY STIMULATING FACTOR 1; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE RELATED PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; BONE METASTASIS; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL DIFFERENTIATION; CELL EXPANSION; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; HEART LEFT VENTRICLE; IMMUNE DEFICIENCY; IN VIVO STUDY; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; SUPPRESSOR CELL; TIBIA; UPREGULATION;

EID: 84881401714     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21990     Document Type: Article

References (35)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29; PMID:22237781; http://dx.doi.org/10.3322/caac.20138.
2. Yan T, Yin W, Zhou Q, Zhou L, Jiang Y, Du Y, et al. The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials. Eur J Cancer 2012; 48:187-95; PMID:22100904; http://dx.doi.org/10.1016/j.ejca.2011.10.021.
3. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27:165-76; PMID:11417967; http://dx.doi.org/10.1053/ctrv.2000.0210.
4. Yoneda T, Sasaki A, Mundy GR. Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat 1994; 32:73-84; PMID:7819589; http://dx.doi.org/10.1007/BF00666208.
5. Sterling JA, Edwards JR, Martin TJ, Mundy GR. Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone 2011; 48:6- 15; PMID:20643235; http://dx.doi.org/10.1016/j.bone.2010.07.015.
6. Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells. Adv Exp Med Biol 2007; 601:213-23; PMID:17713008; http://dx.doi.org/10.1007/978-0-387-72005-0_22.
7. Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer. Cancer J 2010; 16:348- 53; PMID:20693846; http://dx.doi.org/10.1097/PPO.0b013e3181eb3358.
8. Youn JI, Gabrilovich DI. The biology of myeloidderived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 2010; 40:2969-75; PMID:21061430; http://dx.doi.org/10.1002/eji.201040895.
9. Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010; 22:238-44; PMID:20171075; http://dx.doi.org/10.1016/j.coi.2010.01.021.
10. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http://dx.doi.org/10.1038/nri2506.
11. Bronte V, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zamboni P, et al. Identification of a CD11b(+)/ Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000; 96:3838-46; PMID:11090068.
12. Melani C, Chiodoni C, Forni G, Colombo MP. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 2003; 102:2138-45; PMID:12750171; http://dx.doi.org/10.1182/blood-2003-01-0190.
13. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007; 67:4507-13; PMID:17483367; http://dx.doi.org/10.1158/0008-5472.CAN-06-4174.
14. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006; 16:53-65; PMID:16168663; http://dx.doi.org/10.1016/j.semcancer.2005.07.005.
15. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigenspecific T-cell responses. Cancer Res 2004; 64:5839-49; PMID:15313928; http://dx.doi.org/10.1158/0008-5472.CAN-04-0465.
16. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004; 172:989-99; PMID:14707072.
17. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008; 222:162-79; PMID:18364001; http://dx.doi.org/10.1111/j.1600-065X.2008.00602.x.
18. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008; 13:23- 35; PMID:18167337; http://dx.doi.org/10.1016/j.ccr.2007.12.004.
19. Yang L, Edwards CM, Mundy GR. Gr-1+CD11b+ myeloid-derived suppressor cells: formidable partners in tumor metastasis. J Bone Miner Res 2010; 25:1701- 6; PMID:20572008; http://dx.doi.org/10.1002/jbmr.154.
20. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green- Jarvis B, Shyr Y, et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004; 6:409-21; PMID:15488763; http://dx.doi.org/10.1016/j.ccr.2004.08.031.
21. Johnson RW, Nguyen MP, Padalecki SS, Grubbs BG, Merkel AR, Oyajobi BO, et al. TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. Cancer Res 2011; 71:822-31; PMID:21189326; http://dx.doi.org/10.1158/0008-5472.CAN-10-2993.
22. Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 2007; 67:11438-46; PMID:18056472;
23. Talmadge JE, Hood KC, Zobel LC, Shafer LR, Coles M, Toth B. Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion. Int Immunopharmacol 2007; 7:140- 51; PMID:17178380; http://dx.doi.org/10.1016/j.intimp.2006.09.021.
24. Kusmartsev S, Gabrilovich DI. Effect of tumorderived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev 2006; 25:323-31; PMID:16983515; http://dx.doi.org/10.1007/s10555-006-9002-6.
25. Sterling JA, Oyajobi BO, Grubbs B, Padalecki SS, Munoz SA, Gupta A, et al. The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells. Cancer Res 2006; 66:7548-53; PMID:16885353; http://dx.doi.org/10.1158/0008-5472.CAN-06-0452.
26. Burger EH, Van der Meer JW, van de Gevel JS, Gribnau JC, Thesingh GW, van Furth R. In vitro formation of osteoclasts from long-term cultures of bone marrow mononuclear phagocytes. J Exp Med 1982; 156:1604-14; PMID:7175438; http://dx.doi.org/10.1084/jem.156.6.1604.
27. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, et al. HIF-1a regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 2010; 207:2439- 53; PMID:20876310; http://dx.doi.org/10.1084/jem.20100587.
28. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2:584-93; PMID:12154351; http://dx.doi.org/10.1038/nrc867.
29. Percival RC, Urwin GH, Harris S, Yates AJ, Williams JL, Beneton M, et al. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 1987; 13:41-9; PMID:3102281.
30. Suva LJ, Griffin RJ, Makhoul I. Mechanisms of bone metastases of breast cancer. Endocr Relat Cancer 2009: 16:703-13; PMID:19443538; http://dx.doi.org/10.1677/ERC-09-0012.
31. Lathers DM, Clark JI, Achille NJ, Young MR. Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. Cancer Immunol Immunother 2004; 53:422-30; PMID:14648070; http://dx.doi.org/10.1007/s00262-003-0459-7.
32. Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R, et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 2003; 63:4441-9; PMID:12907617.
33. Kusmartsev S, Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 2006; 55:237-45; PMID:16047143; http://dx.doi.org/10.1007/s00262-005-0048-z.
34. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996; 98:1544-9; PMID:8833902; http://dx.doi.org/10.1172/JCI118947.
35. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995; 55:3551-7; PMID:7627963.